Increasing the levels of HSPB1 in the brain extracellular space through strategies to deliver recombinant protein or using astrocyte-directed gene therapy vectors constitutes potential therapeutic avenues in AD and related tauopathies. The gene discussed is HSPB1; the disease is Alzheimer disease.